Quarterly ResultAug 7, 2026, 04:53 PM
bioAffinity Technologies Reports Q2 Net Loss of $3.37M; Going Concern Doubt
AI Summary
bioAffinity Technologies, Inc. reported a net loss of $3.37 million for the second quarter of 2026 and $7.00 million for the first six months of 2026. The company's cash and cash equivalents significantly decreased to $2.43 million by June 30, 2026, leading management to conclude there is substantial doubt about its ability to continue as a going concern. The accumulated deficit reached $75.6 million, highlighting the need for additional capital to support future operations.
Key Highlights
- Management identified substantial doubt about the company's ability to continue as a going concern.
- Reported a net loss of $3.37 million for the three months ended June 30, 2026.
- Net loss for the six months ended June 30, 2026, was $7.00 million.
- Cash and cash equivalents decreased to $2.43 million as of June 30, 2026.
- Net cash used in operating activities was $6.43 million for the first half of 2026.
- Accumulated deficit reached $75.6 million as of June 30, 2026.
- Net revenue for Q2 2026 increased to $1.51 million, while H1 2026 net revenue decreased to $2.86 million.
- Patient service fees, including CyPath® Lung, totaled $2.33 million for H1 2026.
Price Impact
More from BIAF